# From pathogenesis to new therapeutic targets in Diffuse Large B cell Lymphoma

> **NIH NIH R35** · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2021 · $960,000

## Abstract

Project Summary
 This research program is aimed at identifying new pathogenetic mechanisms in Diffuse Large B-Cell
Lymphoma (DLBCL), the most common human lymphoma, as a mean to discover new targets for therapeutic
intervention. DLBCL is a heterogeneous malignancy comprising genetically and clinically distinct phenotypes,
which are derived from the malignant transformation of germinal center (GC) B cells at different stages of
differentiation. Recent analysis of the DLBCL genome has identified a multitude of altered genes, most of
which with unknown roles in normal GC physiology and lymphomagenesis. Thus, our program will address
these issues by two main complementary approaches. First, we will use novel technologies allowing the
analysis of signaling pathways and gene expression on a single cell basis from purified GC B cell
subpopulations, as a mean to comprehensively identify the programs that are involved in GC development and
potentially altered in DLBCL. Second, we will investigate the function and regulation of two GC “master
regulators”, the activity of which is deregulated in DLBCL via mutational mechanisms as well as via alterations
in “upstream” signaling pathways. The overall program is based on our long-standing experience in studying
the biology of the GC reaction in relationship to the genetic mechanisms leading to its malignant
transformation. We expect that the results of the above studies will identify new targets for therapy, which will
be eventually tested pre-clinically in our portfolio of genetically defined mouse models of DLBCL.

## Key facts

- **NIH application ID:** 10224858
- **Project number:** 5R35CA210105-06
- **Recipient organization:** COLUMBIA UNIVERSITY HEALTH SCIENCES
- **Principal Investigator:** Riccardo Dalla-Favera
- **Activity code:** R35 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $960,000
- **Award type:** 5
- **Project period:** 2016-08-04 → 2023-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10224858

## Citation

> US National Institutes of Health, RePORTER application 10224858, From pathogenesis to new therapeutic targets in Diffuse Large B cell Lymphoma (5R35CA210105-06). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10224858. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*